With an arsenal of antibody assets based on IgE, IgA, and IgG, the newly combined company has opportunities across cancer indications.

A phase 1 open-label trial is underway, evaluating the safety and efficacy of CT-95 in patients with mesothelin-expressing ...

Yago Nieto, MD, PhD, discusses AFM13, how it works, and its effect as a bispecific antibody that targets CD30 and CD16.

The ongoing COMPANION-002 trial has been evaluating the candidate, tovecimig (formerly CTX-009), alongside paclitaxel in ...

PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has announced the dosing of the first patient in its Phase 1 ...

The first patient has been dosed in a phase 1 clinical trial of CT-95 among patients with mesothelin-expressing solid tumors.

AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

Context Therapeutics Inc. (NASDAQ: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced that the first patient has been dosed in the Phase 1 clinical trial of ...

CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody CT-95 is Context's second T cell engaging bispecific antibody to enter the clinic in 2025 PHILADELPHIA, April 09, 2025 (GLOBE NEWSWIRE) ...

This milestone marks Context's second active clinical trial, following the dosing of the first patient in the CTIM-76 trial ...

Context Therapeutics (CNTX) announced that the first patient has been dosed in the Phase 1 clinical trial of CT-95, a mesothelin x CD3 T cell ...

ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases ...